CN103127412B - Pharmaceutical composition, and preparation method and application thereof - Google Patents
Pharmaceutical composition, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103127412B CN103127412B CN201310069212.0A CN201310069212A CN103127412B CN 103127412 B CN103127412 B CN 103127412B CN 201310069212 A CN201310069212 A CN 201310069212A CN 103127412 B CN103127412 B CN 103127412B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- insulin resistant
- extract
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical compositions, and particularly provides a pharmaceutical composition for improving insulin resistance, and a preparation method and application thereof. The pharmaceutical composition is composed of the following crude drugs or extracts in parts by weight: 30-60 parts of herba potentilae, 20-30 parts of radix astragali, 50-60 parts of balsam pear, 20-50 parts of Pu-Erh tea and 10-20 parts of dew grass. The extract is prepared by the following steps: extracting the crude drug with water or alcohol to obtain an extracting solution, concentrating the extracting solution to the relative density of 1.25-1.30, drying, and pulverizing to obtain the extract. The pharmaceutical composition provided by the invention can obviously improve insulin resistance, effectively lowers the blood sugar concentration, and has the advantages of low cost and high use safety.
Description
Technical field
The invention belongs to field of medicinal compositions, relate generally to a kind of pharmaceutical composition that improves insulin resistant that Chinese herbal medicine prepared as raw material of take
.
Background technology
Diabetes are common multiple diseases of a kind of serious harm human health, are difficult to cure, and complication extensively and seriously.Expect 2025, diabetes mellitus in China number will reach 3,600 ten thousand, rank global diabetes number second, and most of age of onset be between 45-64.Diabetes can be divided into four types: i.e. type 1 diabetes, type ii diabetes, gestational diabetes and special type diabetes.Type ii diabetes is the coefficient result of h and E factor, accounts for the more than 90% of diabetes total number of persons, is more common in the overweight or fat middle-aged and elderly people of build, has obvious Familial Occurrence.
Insulin resistant refer to body to the biological effect of a certain amount of insulin lower than a kind of phenomenon of estimating normal level, it is the principal character of type ii diabetes, being mainly manifested in insulin suppresses the ability of liver release glucose and promotes surrounding tissue to utilize the ability of glucose to reduce, for regulate blood glucose at normal level, the supersecretion insulin of body compensatory, there is hyperinsulinemia, thereby bring a series of harmful effects to body.Simultaneously, insulin resistant is relevant with the morbidity of the diseases such as arteriosclerotic cardiovascular disease, hypertension, dyslipidemia, visceral adiposity, it is one of the composition of " metabolism syndrome ", and insulin resistant and compensatory hyperinsulinemia are the key links of metabolism syndrome, therefore, improve type ii diabetes patient insulin resistant, to the treatment of diabetes and to reduce the sickness rate of diabetes complicated Other diseases significant.
Euglycemic agent is a kind of by improving the sensitivity of insulin target tissue, promote peripheral tissues's (as fat, liver etc.) to the picked-up of glucose and elimination ability, suppress the effect of the glyconeogenesis of liver, thereby reach, improve insulin resistance, increase the effect of insulin sensitivity.At present, this class medicine is modal is Thiazolidinediones, can effectively reduce the fatty acid levels raising in diabetes mellitus patients with insulin resistance, can obviously change the distribution of body fat tissue simultaneously.Thiazolidinediones can not only improve the control of blood glucose, reduce opposing, and the other parts imbalance situation of what one is particularly good at insulin resistance syndrome taken a turn for the better, image height insulinemia, lipid metabolism confusion, hyperuricemia etc., and can not cause hypoglycemia, extremely people pay close attention to.But this class medicine reduces the exact mechanism of insulin to be not very clear, and the side effect such as edema, cardiac damage.
Long and rich experience for Chinese herbal treatment diabetes, selects that medicine is in extensive range and side effect is little.Pharmaceutical college of Jiangsu University etc. in prior art, at < <, improve in the active ingredient of Chinese herbs of insulin resistant and study on mechanism progress > > thereof and for example analyzed a variety of Chinese crude drugs, to improving the research of insulin resistant: Fructus Lycii, the Radix Astragali, Radix Ginseng, Radix Notoginseng, Radix Panacis Quinquefolii, the Radix Paeoniae Alba, Herba Reineckeae Carneae, Folium Ginkgo, Radix Scutellariae, Folium Crataegi, resveratrol, Radix Puerariae, Herba Houttuyniae, Fructus Phyllanthi.But do not work out suitable pharmaceutical composition.Therefore, study a kind of special in the Chinese medicine composition that improves insulin resistant, significant.
Summary of the invention
For the existing deficiency of improving insulin resistant medicine, the present invention aims to provide a kind of pharmaceutical composition, this pharmaceutical composition is comprised of Herba Potentillae Discoloris, the Radix Astragali, Fructus Momordicae charantiae, Folium camelliae assamicae, Radix Cyanotis vagae, this pharmaceutical composition can improve the opposing of insulin significantly, effectively reduce blood sugar concentration, and cost is low, use safety.
For achieving the above object, technical scheme of the present invention is:
Improve a pharmaceutical composition for insulin resistant, by medicine crude drug in whole or the extract of following weight portion, formed:
Herba Potentillae Discoloris 30-60 part, Radix Astragali 20-30 part, Fructus Momordicae charantiae 50-60 part, Folium camelliae assamicae 20-50 part, Radix Cyanotis vagae 10-20 part;
Described extract is that crude drug in whole obtains extracting solution after water or alcohol extraction, and it is 1.25-1.30 that extracting solution is concentrated into relative density, the extract obtaining after being then dried, pulverizing.
Preferably medicine crude drug in whole or the extract by following weight portion forms:
50 parts of Herba Potentillae Discoloris, 30 parts of the Radixs Astragali, 60 parts, Fructus Momordicae charantiae, 30 parts of Folium camelliae assamicaes, 10 parts of Radix Cyanotis vagae.
In addition, also preferred medicine crude drug in whole or extract by following weight portion forms:
60 parts of Herba Potentillae Discoloris, 20 parts of the Radixs Astragali, 50 parts, Fructus Momordicae charantiae, 40 parts of Folium camelliae assamicaes, 10 parts of Radix Cyanotis vagae.
The dosage form of this pharmaceutical composition is preferably tablet or capsule.
The preparation method of described pharmaceutical composition, is selected from one of following two kinds of methods:
Method one: raw medicinal material is cleaned respectively, pulverized, cross 60-80 mesh sieve, mix by above-mentioned weight portion, obtain pharmaceutical composition of the present invention;
Method two: raw medicinal material is cleaned respectively, pulverized, cross 60-80 mesh sieve, then by above-mentioned weight portion, Herba Potentillae Discoloris after sieving, Fructus Momordicae charantiae, Folium camelliae assamicae are merged, water heating and refluxing extraction repeatedly, merge extractive liquid,, it is 1.25-1.30 that extracting solution is concentrated into relative density, dry, obtains component A; The Radix Astragali after sieving, Radix Cyanotis vagae are merged, add alcohol and soak, then ultrasonic extraction, filters, and filtrate is concentrated, dry, obtains B component; Component A and B component are mixed, obtain pharmaceutical composition of the present invention.
Method two is preferably: raw medicinal material is cleaned respectively, pulverized, cross 60-80 mesh sieve, then by above-mentioned weight portion, Herba Potentillae Discoloris after sieving, Fructus Momordicae charantiae, Folium camelliae assamicae are merged, and water heating and refluxing extraction 1-3 time is extracted 1-2 hour at every turn, merge extractive liquid,, it is 1.25-1.30 that extracting solution is concentrated into relative density, dry, obtains component A; The Radix Astragali after sieving, Radix Cyanotis vagae are merged, add alcohol and soak 12-48 hour at 20 ℃-25 ℃, then supersound extraction 30-60 minute, filters, and it is 1.25-1.30 that filtrate is concentrated into relative density, dry, obtains B component; Component A and B component are mixed, pulverize, obtain pharmaceutical composition of the present invention.
Described alcohol is the ethanol that mass concentration is preferably 30%-95%.
Described pharmaceutical composition improves the application in insulin resistant medicine in preparation.
Below the present invention will be further explained:
The water extraction liquid of Herba Potentillae Discoloris has the good effect that improves insulin resistant; , the Radix Astragali has the effect of defying age, blood fat reducing and enhancing human body immunity power; Fructus Momordicae charantiae is vegetable in a kind of medicine of medicine-food two-purpose, and bitter melon polysaccharide has blood sugar lowering, antiviral and the effect such as antibacterial; Ecdyson in Radix Cyanotis vagae etc. has obvious hypoglycemic activity; And Folium camelliae assamicae has effect for reducing fat; So its five kinds of compositions are combined use, can have the effect that Synergistic improves insulin resistant, meanwhile, can there is the effect of antioxidation, blood fat reducing and enhancing human body immunity power, the cause of disease that can form for insulin resistant, effectively alleviates insulin resistant.
Compared with prior art, advantage of the present invention is:
1, the crude drug in whole of the present composition or the preparation method of extract, easy to be reasonable, the production method providing is all suitable for large-scale industrialization produces, and cost is low; The effect of insulin resistant that improves significantly of the equal tool of the crude drug in whole of compositions or extract, and have no side effect.
2, the effective ingredient of pharmaceutical composition of the present invention has the good external effect that improves insulin resistant, first show as 3T3-L1 cell insulin resistant model tool is significantly improved to effect, also show as the effect that diabetes insulin opposing rat is significantly improved to insulin resistant.
The specific embodiment
Below in conjunction with embodiment, content of the present invention is described in further detail, but within should not be construed as the scope that protection scope of the present invention is only limited to following embodiment.
embodiment 1:
Crude drug formula is:
Herba Potentillae Discoloris 50g, Radix Astragali 30g, Fructus Momordicae charantiae 60g, Folium camelliae assamicae 30g, Radix Cyanotis vagae 10g.
Preparation method:
A, according to crude drug part by weight, take Chinese crude drug, clean, powder becomes powder to cross 60 mesh sieves, standby;
B, Herba Potentillae Discoloris, Fructus Momordicae charantiae, Folium camelliae assamicae merge, and decoct with water twice, add for the first time 15 times of water gagings, decoct 2 hours, add for the second time 8 times of water gagings of water, decoct collecting decoction 1 hour, filter, it is 1.25-1.30(60 ℃ that filtrate is concentrated into relative density) thick paste, 68 ℃ of dry for standby;
C, the Radix Astragali, Radix Cyanotis vagae merge, and add 15 times of amount 75% soak with ethanol after 24 hours, and 500W ultrasonic extraction 30 minutes, filters, and it is 1.25-1.30(60 ℃ that filtrate is concentrated into relative density) thick paste, 68 ℃ of dry for standby;
D, the dry cream of step b gained water extraction, step c gained alcohol are promoted to cream mix, pulverize (hereinafter referred to as FL1);
E, step a gained powder is merged to (hereinafter referred to as FL2).
embodiment 2:
Crude drug formula is:
Herba Potentillae Discoloris 60g, Radix Astragali 20g, Fructus Momordicae charantiae 50g, Folium camelliae assamicae 40g, Radix Cyanotis vagae 10g.
Preparation method:
A, according to crude drug part by weight, take Chinese crude drug, clean, powder becomes powder to cross 60 mesh sieves, standby;
B, Herba Potentillae Discoloris, Fructus Momordicae charantiae, Folium camelliae assamicae merge, and decoct with water twice, add for the first time 15 times of water gagings, decoct 2 hours, add for the second time 8 times of water gagings of water, decoct collecting decoction 1 hour, filter, it is 1.25-1.30(60 ℃ that filtrate is concentrated into relative density) thick paste, 68 ℃ of dry for standby;
C, the Radix Astragali, Radix Cyanotis vagae merge, and add 15 times of amount 75% soak with ethanol after 24 hours, and 500W ultrasonic extraction 30 minutes, filters, and it is 1.25-1.30(60 ℃ that filtrate is concentrated into relative density) thick paste, 68 ℃ of dry for standby;
D, the dry cream of step b gained water extraction, step c gained alcohol are promoted to cream mix, pulverize (hereinafter referred to as FL3);
E, step a gained powder is merged to (hereinafter referred to as FL4).
embodiment 3:
Pharmaceutical composition effective ingredient FL1 of the present invention, FL2, FL3, FL4 improve the experiment in vitro of Insulin Resistance
1, set up 3T3-L1 cell insulin resistant model
With DMEM in high glucose culture medium by 3T3-L1 cell culture on 6 orifice plates, until cell, cover with and reach after certain density, change into and contain certain density insulin, the culture medium increment of dexamethasone and IBMX is cultivated, after cell differentiation reaches to a certain degree, cell is inoculated in to normal culture medium culturing 2 days for 24 orifice plates, after 2 days, start reactance, using 2 holes as blank, all the other are with containing insulin, the culture medium culturing of dexamethasone, induce after 5 days, detect concentration of glucose in cell culture medium, when 0.5-1 that the concentration of glucose of reactance reaches blank concentration of glucose doubly after, can confirm opposing establishment.
2, Chinese medicine compositions effective ingredient FL1 of the present invention, FL2, FL3, FL4 measure 3T3-L1 cell insulin resistant model improvement effect
Chinese medicine compositions effective ingredient FL1 of the present invention, FL2, FL3, FL4 are made into the sterile liquid that concentration is 8mg/ml with phosphate buffer, and with the positive contrast of maleic acid lattice row ketone (ROG), being made into concentration is 2*10
-3the sterile liquid of M.If blank hole, model control wells, positive control hole and medicine hole, dosing, each medicine final concentration is respectively: ROG 2*10
-5, FL1, FL2, FL3, FL4 are 80 mcg/ml.Within after dosing two days, detecting each hole glucose final concentration changes.The results are shown in Table 1
The concentration determination of table 1 glucose (mM)
By table 1 result, can be found out, administration ROG, FL1, FL2, FL3, FL3 concentration of glucose are higher than blank group, but be all starkly lower than model control group, show that thus the pharmaceutical composition effective ingredient of invention is significantly improved effect to 3T3-L1 cell insulin resistant model tool.
embodiment 4
The impact of pharmaceutical composition effective ingredient FL3 of the present invention on insulin resistance rat
Body weight is all the Wistar of 280g-350g rat, and male and female half and half ，You Central South University provides.Get at random 8 rats as blank group (male and female half and half), all the other rat muscle injection dexamethasone sodium phosphate injection (Jilin Aodong Pharmaceutical Group Yanji Co., Ltd) 1mg/kg, every other day once, inject 30 days altogether.After 30 days, rat is divided into six groups, be respectively: blank group (normal saline), model group, positive drug group ROG(rosiglitazone) 3mg/kg.day, pharmaceutical composition thing FL3 high dose group of the present invention (100mg/kg.day gavage), dosage group in pharmaceutical composition FL3 of the present invention (80mg/kg.day gavage), pharmaceutical composition FL3 low dose group of the present invention (60mg/kg.day gavage), gavage is cultivated 3 weeks, every day gavage secondary, the gavage time is in the morning during 9-10 and carry out during 16-18 afternoon, before administration, after administration, measure fasting glucose, serum insulin concentration.
The impact of table 2 Chinese medicine compositions of the present invention effective ingredient on insulin resistance rat
Note: compare * P<0.05 with model group
From table 2 result: administration is after 3 weeks, and each administration group (ROG, high, the middle dosage of pharmaceutical composition FL3 of the present invention) fasting glucose is compared with model group, and there were significant differences (P<0.05); Serum insulin levels is compared with model group, and each administration group (ROG, the high, medium and low dosage of pharmaceutical composition FL3 of the present invention) fasting glucose is compared with model group, and all there were significant differences (P<0.05).Insulin resistance index is compared with model group, all obviously reductions of pharmaceutical composition FL3 senior middle school's low dose group of the present invention, the wherein middle even significant difference of dosage group (P<0.05).
Above result demonstration, pharmaceutical composition of the present invention is significantly improved the effect of insulin resistant to diabetes insulin opposing rat.
Claims (7)
1. for improving a pharmaceutical composition for insulin resistant, it is characterized in that, by medicine crude drug in whole or the extract of following weight portion, formed:
Herba Potentillae Discoloris 30-60 part, Radix Astragali 20-30 part, Fructus Momordicae charantiae 50-60 part, Folium camelliae assamicae 20-50 part, Radix Cyanotis vagae 10-20 part;
Described extract is that crude drug in whole obtains extracting solution after water or alcohol extraction, the extract that extracting solution obtains after concentrating, be dried, pulverize.
2. according to claim 1 for improving the pharmaceutical composition of insulin resistant, it is characterized in that, by medicine crude drug in whole or the extract of following weight portion, formed:
50 parts of Herba Potentillae Discoloris, 30 parts of the Radixs Astragali, 60 parts, Fructus Momordicae charantiae, 30 parts of Folium camelliae assamicaes, 10 parts of Radix Cyanotis vagae.
3. according to claim 1 for improving the pharmaceutical composition of insulin resistant, it is characterized in that, by medicine crude drug in whole or the extract of following weight portion, formed:
60 parts of Herba Potentillae Discoloris, 20 parts of the Radixs Astragali, 50 parts, Fructus Momordicae charantiae, 40 parts of Folium camelliae assamicaes, 10 parts of Radix Cyanotis vagae.
According to one of claim 1-3 Suo Shu for improving the pharmaceutical composition of insulin resistant, it is characterized in that, the dosage form of this pharmaceutical composition is tablet or capsule.
5. one of claim 1-4 is described is characterized in that for improving the preparation method of the pharmaceutical composition of insulin resistant, is selected from one of following two kinds of methods:
Method one: raw medicinal material is cleaned respectively, pulverized, cross 60-80 mesh sieve, mix by the described weight portion of one of claim 1-4, obtain pharmaceutical composition;
Method two: raw medicinal material is cleaned respectively, pulverized, cross 60-80 mesh sieve, then by one of claim 1-4 described weight portion, Herba Potentillae Discoloris after sieving, Fructus Momordicae charantiae, Folium camelliae assamicae are merged, water heating and refluxing extraction repeatedly, merge extractive liquid,, extracting solution is concentrated, dry, obtains component A; The Radix Astragali after sieving, Radix Cyanotis vagae are merged, add alcohol and soak, then ultrasonic extraction, filters, and filtrate is concentrated, dry, obtains B component; Component A and B component are mixed, obtain pharmaceutical composition.
6. according to claim 5 for improving the preparation method of the pharmaceutical composition of insulin resistant, it is characterized in that, described alcohol is that mass concentration is the ethanol of 30%-95%.
7. the described pharmaceutical composition of one of claim 1-4 improves the application in insulin resistant medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310069212.0A CN103127412B (en) | 2013-03-05 | 2013-03-05 | Pharmaceutical composition, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310069212.0A CN103127412B (en) | 2013-03-05 | 2013-03-05 | Pharmaceutical composition, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103127412A CN103127412A (en) | 2013-06-05 |
| CN103127412B true CN103127412B (en) | 2014-02-26 |
Family
ID=48488282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310069212.0A Active CN103127412B (en) | 2013-03-05 | 2013-03-05 | Pharmaceutical composition, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127412B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317774A (en) * | 2018-03-29 | 2019-10-11 | 玛旺干细胞医学生物科技股份有限公司 | Aqueous extract of Chinese herbal medicine and combinations thereof and purposes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101194998A (en) * | 2007-11-28 | 2008-06-11 | 韩曙光 | Chinese medicine for treating diabetes |
-
2013
- 2013-03-05 CN CN201310069212.0A patent/CN103127412B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101194998A (en) * | 2007-11-28 | 2008-06-11 | 韩曙光 | Chinese medicine for treating diabetes |
Non-Patent Citations (1)
| Title |
|---|
| 南京中医药大学.翻白草、黄芪、苦瓜.《中药大辞典第二版》.2006,1753、2812、3821. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103127412A (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071048B (en) | Traditional Chinese medicine composition for treating alzheimer diseases and preparation method of traditional Chinese medicine composition | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN102357226A (en) | Application of Chinese herbal medicine turmeric extraction in preparation of slimming and lipid-lowering drug or drug with lipase activity inhibition effect | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN104474472A (en) | Broadleaf holly leaf buccal tablet capable of reducing high blood pressure, high blood lipid and high blood glucose and production method of buccal tablet | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN103127412B (en) | Pharmaceutical composition, and preparation method and application thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102366433A (en) | Application of Chinese medicinal chrysanthemum extract in preparing weight-losing and lipid-lowering medicaments or lipase activity-inhibiting medicaments | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN103505664A (en) | Blood lipid reducing composition containing semen cassiae and preparation method of composition | |
| CN100528185C (en) | Chinese medicine capsule for treating AIDS and its preparing method | |
| CN102370763A (en) | Application of Chinese medicinal herb immature bitter orange extract to preparation of weight-reducing and lipid-lowering medicament or preparation of medicament having lipase activity suppressing effect | |
| CN105327115A (en) | Phellinus linteus catharsis formula for prevention and cure of type II diabetes and preparation process thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN102370708A (en) | Application of extracts of Chinese herbal medicine mulberry leaf in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity | |
| CN104055963A (en) | Fat loss traditional Chinese medicine composition and preparation method thereof | |
| CN102188469A (en) | Chrysanthemum morifolium extractive with live protection function, extraction method and applications thereof | |
| CN1080863A (en) | A kind of health medicine compositions of relieving the effect of alcohol | |
| CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
| CN101352484B (en) | Medicament composition for treating acute and chronic hepatitis | |
| CN101912460A (en) | Preparation method for improving ginsenoside-containing Chinese medicinal extract quality | |
| US20220257688A1 (en) | Composition comprising salvia miltiorrhiza or paeonia lactiflora extract as active ingredient for prevention or treatment of lipid metabolism disorder | |
| CN101406576A (en) | Chinese medicine for treating diabetes and preparation method | |
| CN102397304A (en) | Application of Chinese herbal medicine ginkgo biloba extract to preparation of medicament for reducing weight and lipid or preparation of medicament with lipase activity inhibitory action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |